Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Colorectal Neoplasms 2Colonic Neoplasms 2Sarcoma, Synovial 1Sarcoma 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 6tazemetostat 5fludarabine 4pembrolizumab 2soblidotin 1reolysin 1pazopanib 1drozitumab 1cixutumumab 1atezolizumab 1anlotinib 1Tablets 1Rosuvastatin Calcium 1Rifampin 1Ramucirumab 1Radiation 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Midazolam 1Itraconazole 1Injections 1Immunotherapy, Adoptive 1Immunotherapy 1Imatinib Mesylate 1Ifosfamide 1Gemcitabine 1Drug Therapy 1Doxorubicin 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Sarcoma, Synovial × drozitumab × Clear all
NCT00543712 2022-12-13

A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)

Genentech, Inc.

Phase 2 Terminated
15 enrolled
Sarcoma

Chondrosarcoma, Sarcoma, Sarcoma, Synovial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡